MRM Health NV announced that it has received 14,250,000 in an equity round of funding on February 19, 2020. The transaction will include participation from new investor DuPont Nutrition & Biosciences through DuPont de Nemours, Inc., Qbic II, a fund managed by QBIC Venture Partners, and VIB BV., and returning investors, Ackermans & Van Haaren NV for 4,000,000 and more than 15% stake, and MRM Technologies.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.09 USD | +1.20% | +2.78% | +6.71% |
05-28 | DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says | MT |
05-28 | North American Morning Briefing : PCE Inflation -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.71% | 33.92B | |
+1.05% | 75.73B | |
-1.16% | 47.26B | |
+12.26% | 18.48B | |
+12.15% | 11.79B | |
-1.50% | 10.72B | |
-21.32% | 10.29B | |
+1.06% | 9.22B | |
-8.06% | 8.23B | |
-4.69% | 7.39B |
- Stock Market
- Equities
- DD Stock
- News DuPont de Nemours, Inc.
- MRM Health NV announced that it has received €14.25 million in funding from DuPont de Nemours, Inc., Ackermans & Van Haaren NV, VIB BV, QBIC Venture Partners, MRM Technologies N.V.